Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study to Assess Safety and Quality of Life of Patients Using Biojector Versus Needles for Fuzeon Administration

This study has been completed.
Roche Pharma AG
Information provided by (Responsible Party):
Canadian Immunodeficiency Research Collaborative Identifier:
First received: June 2, 2006
Last updated: June 4, 2012
Last verified: June 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2008
  Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)